Sign In
Buy KROS
$10.50
-0.0500 (-0.474%)
At Close: Jun 03, 2026
LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Announces Pricing of Public Offering of Common Stock
10:11pm, Thursday, 12'th Nov 2020
LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Announces Proposed Public Offering of Common Stock
05:12pm, Tuesday, 10'th Nov 2020
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
04:17pm, Tuesday, 10'th Nov 2020
LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev
Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition
04:01pm, Wednesday, 04'th Nov 2020
LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 19)
10X Genomics Inc (NASDAQ: TXG)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Avenue Therapeutics Inc (NASDAQ: ATXI)...
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results
11:00am, Thursday, 13'th Aug 2020
LEXINGTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci
Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series
12:00pm, Monday, 10'th Aug 2020
LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev
Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update
12:00pm, Tuesday, 04'th Aug 2020
LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, dev
Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation
02:12pm, Wednesday, 29'th Jul 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Keros Therapeutics Set to Join Russell 2000® Index
11:01am, Friday, 26'th Jun 2020
Keros Therapeutics, Inc. (“Keros” or the “Company”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patie
Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher
12:34pm, Wednesday, 24'th Jun 2020
Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Poster presentations introduce data demonstrating KER-050 robustly promoted hematopoiesis in multiple animal species in preclinical studies and support a potentially novel mechanism of action. Oral p
Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference
11:01am, Thursday, 28'th May 2020
Keros Therapeutics, Inc. (“Keros”) (KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from he
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
11:00am, Friday, 22'nd May 2020
LEXINGTON, Mass., May 22, 2020 -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and.
